We are live on
!
Find out more
BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$1.11B
1-Year Est. Return
171.34%
This Fund
S&P 500
This Quarter
Est. Return
+12.19%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$85.8M
(+5.6%)
Cap. Flow
+$186M
Cap. Flow
% of AUM
11.54%
Top 10 Holdings %
Top 10 Hldgs %
76.11%
Holding
34
New
4
Increased
2
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rapid Micro Biosystems
RPID
|
+$174M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$99.5M |
| 3 |
Invivyd
IVVD
|
+$92.3M |
| 4 |
Tango Therapeutics
TNGX
|
+$12M |
| 5 |
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
|
+$4.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$77.1M |
| 2 |
Atea Pharmaceuticals
AVIR
|
+$53.1M |
| 3 |
DVAX
Dynavax Technologies
DVAX
|
+$44.6M |
| 4 |
Kymera Therapeutics
KYMR
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.57% |
| 2 | Financials | 2.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARYD
26
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $7.04M | 0.44% |
700,000
| – | – |
|
|
ARYE
27
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $4.94M | 0.31% |
+500,000
| New | +$4.97M |
|
|
PANA
28
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| $4.88M | 0.3% |
500,000
| – | – |
|
|
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $4.86M | 0.3% |
487,500
| – | – |
|
|
OMEG
30
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
| $3.89M | 0.24% |
400,000
| – | – |
|
|
FLACU
31
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $3.01M | 0.19% |
300,000
| – | – |
|
|
JYAC
32
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $2.92M | 0.18% |
300,000
| – | – |
|
33
MoonLake Immunotherapeutics
MLTX
$1.47B
| $2.49M | 0.15% |
250,000
| – | – |
|
|
34
Kymera Therapeutics
KYMR
$9.48B
| – | – |
-479,605
| Closed | -$23.3M |
|
Similar funds
JTWM
HH
RIM
YL
FLAM
AIM
MTCM
CNC
Bain Capital Life Sciences Investors's Q3 2021 Portfolio in Review
As of Q3 2021, Bain Capital Life Sciences Investors held 34 positions worth $1.61B, up 5.6% from $1.53B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Bain Capital Life Sciences Investors deployed $186M of net new capital in Q3 2021, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Rapid Micro Biosystems: 8,434,560 shares worth $156M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 88% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $77.1M trimmed.
- Bain Capital Life Sciences Investors's largest Q3 2021 buy was Rapid Micro Biosystems: 8,434,560 shares worth $156M.
- Bain Capital Life Sciences Investors added most to Tango Therapeutics in Q3 2021, an estimated $12M increase.
- Bain Capital Life Sciences Investors's biggest Q3 2021 reduction was SpringWorks Therapeutics, cutting an estimated $77.1M.
- Bain Capital Life Sciences Investors fully exited Kymera Therapeutics in Q3 2021, selling an estimated $23.3M.
- Bain Capital Life Sciences Investors's ten largest holdings make up 76% of its $1.61B portfolio in Q3 2021.
- Bain Capital Life Sciences Investors opened 4 new positions and closed 1 in Q3 2021.
- Bain Capital Life Sciences Investors's portfolio value rose 5.6% quarter-over-quarter to $1.61B.
Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2021, filed 15 Nov 2021.